Minireview: MIRomics in Endocrinology: A Novel Approach for Modeling Endocrine Diseases

od Szabó, Péter M., Butz, Henriett, Igaz, Péter, Rácz, Károly, Hunyady, László, Patócs, Attila
Izdano u Mol Endocrinol (2013)

miRNA-target network reveals miR-124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1

od Butz, Henriett, Szabó, Peter M., Khella, Heba W.Z., Nofech-Mozes, Roy, Patocs, Attila, Yousef, George M.
Izdano u Oncotarget (2015)

Integrative analysis of neuroblastoma and pheochromocytoma genomics data

od Szabó, Peter M, Pintér, Miklós, Szabó, Diana Rita, Zsippai, Adrienn, Patócs, Attila, Falus, András, Rácz, Károly, Igaz, Peter
Izdano 2012

mRNA and microRNA expression patterns in adrenocortical cancer

od Zsippai, Adrienn, Szabó, Diana Rita, Szabó, Peter M, Tömböl, Zsófia, Bendes, Melinda R, Nagy, Zoltán, Rácz, Károly, Igaz, Peter
Izdano 2011

Nivolumab in Patients with Advanced Platinum-Resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275

od Galsky, Matthew D., Saci, Abdel, Szabo, Peter M., Han, G. Celine, Grossfeld, Gary, Collette, Sandra, Siefker-Radtke, Arlene, Necchi, Andrea, Sharma, Padmanee
Izdano u Clin Cancer Res (2020)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC

od Ross-Macdonald, Petra, Walsh, Alice M, Chasalow, Scott D, Ammar, Ron, Papillon-Cavanagh, Simon, Szabo, Peter M, Choueiri, Toni K, Sznol, Mario, Wind-Rotolo, Megan
Izdano u J Immunother Cancer (2021)

Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies

od Módos, Dezső, Bulusu, Krishna C., Fazekas, Dávid, Kubisch, János, Brooks, Johanne, Marczell, István, Szabó, Péter M., Vellai, Tibor, Csermely, Péter, Lenti, Katalin, Bender, Andreas, Korcsmáros, Tamás
Izdano u NPJ Syst Biol Appl (2017)

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer

od Wang, Li, Gong, Yixuan, Saci, Abdel, Szabo, Peter M., Martini, Alberto, Necchi, Andrea, Siefker-Radtke, Arlene, Pal, Sumanta, Plimack, Elizabeth R., Sfakianos, John P., Bhardwaj, Nina, Horowitz, Amir, Farkas, Adam M., Mulholland, David, Fischer, Bruce S., Oh, William K., Sharma, Padmanee, Zhu, Jun, Galsky, Matthew D.
Izdano u Eur Urol (2019)

Multiple SARS-CoV-2 Introductions Shaped the Early Outbreak in Central Eastern Europe: Comparing Hungarian Data to a Worldwide Sequence Data-Matrix

od Kemenesi, Gábor, Zeghbib, Safia, Somogyi, Balázs A, Tóth, Gábor Endre, Bányai, Krisztián, Solymosi, Norbert, Szabo, Peter M, Szabó, István, Bálint, Ádám, Urbán, Péter, Herczeg, Róbert, Gyenesei, Attila, Nagy, Ágnes, Pereszlényi, Csaba István, Babinszky, Gergely Csaba, Dudás, Gábor, Terhes, Gabriella, Zöldi, Viktor, Lovas, Róbert, Tenczer, Szabolcs, Kornya, László, Jakab, Ferenc
Izdano u Viruses (2020)

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

od Wang, Li, Saci, Abdel, Szabo, Peter M., Chasalow, Scott D., Castillo-Martin, Mireia, Domingo-Domenech, Josep, Siefker-Radtke, Arlene, Sharma, Padmanee, Sfakianos, John P., Gong, Yixuan, Dominguez-Andres, Ana, Oh, William K., Mulholland, David, Azrilevich, Alex, Hu, Liangyuan, Cordon-Cardo, Carlos, Salmon, Hélène, Bhardwaj, Nina, Zhu, Jun, Galsky, Matthew D.
Izdano u Nat Commun (2018)

Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer

od Kummar, Shivaani, Oza, Amit M., Fleming, Gini F., Sullivan, Daniel M., Gandara, David R., Naughton, Michael J., Villalona-Calero, Miguel A., Morgan, Robert J., Szabo, Peter M., Youn, Ahrim, Chen, Alice P., Ji, Jiuping, Allen, Deborah E., Lih, Chih-Jian, Mehaffey, Michele G., Walsh, William D., McGregor, Paul M., Steinberg, Seth M., Williams, Paul M., Kinders, Robert J., Conley, Barbara A., Simon, Richard M., Doroshow, James H.
Izdano u Clin Cancer Res (2015)

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

od Skoulidis, Ferdinandos, Goldberg, Michael E., Greenawalt, Danielle M., Hellmann, Matthew D., Awad, Mark M., Gainor, Justin F., Schrock, Alexa B., Hartmaier, Ryan J., Trabucco, Sally E., Gay, Laurie, Ali, Siraj M., Elvin, Julia A., Singal, Gaurav, Ross, Jeffrey S., Fabrizio, David, Szabo, Peter M., Chang, Han, Sasson, Ariella, Srinivasan, Sujaya, Kirov, Stefan, Szustakowski, Joseph, Vitazka, Patrik, Edwards, Robin, Bufill, Jose A., Sharma, Neelesh, Ou, Sai-Hong I., Peled, Nir, Spigel, David R., Rizvi, Hira, Aguilar, Elizabeth Jimenez, Carter, Brett W., Erasmus, Jeremy, Halpenny, Darragh F., Plodkowski, Andrew J., Long, Niamh M., Nishino, Mizuki, Denning, Warren L., Galan-Cobo, Ana, Hamdi, Haifa, Hirz, Taghreed, Tong, Pan, Wang, Jing, Rodriguez-Canales, Jaime, Villalobos, Pamela A., Parra, Edwin R., Kalhor, Neda, Sholl, Lynette M., Sauter, Jennifer L., Jungbluth, Achim A., Mino-Kenudson, Mari, Azimi, Roxana, Elamin, Yasir Y., Zhang, Jianjun, Leonardi, Giulia C., Jiang, Fei, Wong, Kwok-Kin, Lee, J. Jack, Papadimitrakopoulou, Vassiliki A., Wistuba, Ignacio I., Miller, Vincent A., Frampton, Garrett M., Wolchok, Jedd D., Shaw, Alice T., Jänne, Pasi A., Stephens, Philip J., Rudin, Charles M., Geese, William J., Albacker, Lee A., Heymach, John V.
Izdano u Cancer Discov (2018)